Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corp Stock Forecast & Price Prediction

Live Integra LifeSciences Holdings Corp Stock (IART) Price
$19.28

15

Ratings

  • Buy 9
  • Hold 6
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$19.28

P/E Ratio

64.69

Volume Traded Today

$2.2M

Dividend

Dividends not available for IART

52 Week High/low

45.42/16.81

Integra LifeSciences Holdings Corp Market Cap

$1.46B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $IART ๐Ÿ›‘

Before you buy IART you'll want to see this list of ten stocks that have huge potential. Want to see if IART made the cut? Enter your email below

IART Summary

Based on ratings from 15 stock analysts, the Integra LifeSciences Holdings Corp stock price is expected to increase by 39.42% in 12 months. This is calculated by using the average 12-month stock price forecast for Integra LifeSciences Holdings Corp. The lowest target is $16 and the highest is $40. Please note analyst price targets are not guaranteed and could be missed completely.

IART Analyst Ratings

IART is a stock in Healthcare which has been forecasted to be worth $26.88 as an average. On the higher end, the forecast price is $40 USD by from Jefferies and on the lower end IART is forecasted to be $16 by Joanne Wuensch from Citigroup.

IART stock forecast by analyst

These are the latest 20 analyst ratings of IART.

Analyst/Firm

Rating

Price Target

Change

Date

Richard Newitter
Truist Securities

Hold

$21

Maintains

Oct 14, 2024
Craig Bijou
B of A Securities

Underperform

$18

Maintains

Oct 7, 2024
Ryan Zimmerman
BTIG

Neutral


Upgrade

Oct 7, 2024
Joanne Wuensch
Citigroup

Sell

$16

Maintains

Oct 1, 2024
Ryan Zimmerman
BTIG

Sell

$20

Maintains

Aug 28, 2024
Joanne Wuensch
Citigroup

Sell

$20

Maintains

Aug 22, 2024
Ryan Zimmerman
BTIG

Sell

$22

Downgrade

Jul 30, 2024
Richard Newitter
Truist Securities

Hold

$26

Maintains

Jul 30, 2024
Joanne Wuensch
Citigroup

Sell

$23

Downgrade

Jul 30, 2024
David Turkaly
JMP Securities

Market Outperform

$35

Maintains

Jul 30, 2024
Richard Newitter
Truist Securities

Hold

$32

Maintains

Jul 16, 2024
Drew Ranieri
Morgan Stanley

Underweight

$27

Maintains

Jul 15, 2024

Citigroup

Neutral


Maintains

Jul 11, 2024
Joanne Wuensch
Citigroup

Neutral

$30

Maintains

Jul 10, 2024
Joanne Wuensch
Citigroup

Neutral

$28

Maintains

May 22, 2024
Drew Ranieri
Morgan Stanley

Underweight

$24

Maintains

May 7, 2024
David Turkaly
JMP Securities

Market Outperform

$40

Maintains

May 7, 2024
Craig Bijou
B of A Securities

Underperform

$26

Maintains

May 7, 2024
Richard Newitter
Truist Securities

Hold

$25

Maintains

May 7, 2024
Vik Chopra
Wells Fargo

Equal-Weight

$25

Downgrade

May 7, 2024

IART Company Information

What They Do: Manufactures surgical and wound care products.

Business Model: The company operates primarily through two segments: Codman Specialty Surgical and Tissue Technologies. It generates revenue by selling a wide range of surgical instruments and products for neurosurgery, wound care, and other medical applications directly to hospitals, surgery centers, and various healthcare providers across multiple regions.

Other Information: Founded in 1989 and headquartered in Princeton, New Jersey, the company has a diverse product portfolio that includes neurosurgery equipment, regenerative technology for wound treatment, and surgical repair products. Its extensive distribution channels and after-market services enhance its market presence and customer relationships.
IART
Integra LifeSciences Holdings Corp (IART)

When did it IPO

1995

Staff Count

3,946

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Jan De Witte

Market Cap

$1.46B

Integra LifeSciences Holdings Corp (IART) Financial Data

In 2023, IART generated $1.54B in revenue, which was a decrease of -1.03% from the previous year. This can be seen as a signal that IART's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$1.37B

Revenue From 2021

$1.54B

12.43 %
From Previous Year

Revenue From 2022

$1.56B

0.99 %
From Previous Year

Revenue From 2023

$1.54B

-1.03 %
From Previous Year
  • Revenue TTM $1.57B
  • Operating Margin TTM 11.3%
  • Gross profit TTM $884.7M
  • Return on assets TTM 3.5%
  • Return on equity TTM 1.5%
  • Profit Margin 1.5%
  • Book Value Per Share 19.78%
  • Market capitalisation $1.46B
  • Revenue for 2021 $1.54B
  • Revenue for 2022 $1.56B
  • Revenue for 2023 $1.54B
  • EPS this year (TTM) $0.29

Integra LifeSciences Holdings Corp (IART) Latest News

News Image

Mon, 14 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Integra LifeSciences (NASDAQ: IART) will release Q3 2024 financial results on November 4, 2024, before market open, followed by a conference call at 8:30 a.m. ET.

Why It Matters - Integra LifeSciences' upcoming earnings report may influence stock price and investor sentiment, providing insights into financial health and growth prospects within the medical technology sector.

News Image

Fri, 04 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Integra's strong growth in the Tissue Technologies and CSS segments has enhanced investor confidence in the stock.

Why It Matters - Integra's growth in key business segments signals robust demand and potential for increased revenue, enhancing stock appeal and encouraging investment.

News Image

Thu, 19 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Kaskela Law LLC is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) following a securities fraud complaint related to shareholder purchases from March 2019 to May 2023.

Why It Matters - The investigation into Integra LifeSciences over alleged securities fraud may signal potential legal and financial risks, impacting share prices and investor confidence.

News Image

Wed, 04 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Integra LifeSciences (IART) CFO Lea Knight will present at the Wells Fargo Healthcare conference on September 4, 2024, at 1:30 PM ET.

Why It Matters - Lea Knight's presentation at a major healthcare conference could signal strategic insights or updates for Integra LifeSciences, influencing stock performance and investor sentiment.

News Image

Wed, 04 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Integra LifeSciences (NASDAQ: IART) CFO Lea Knight will present at the Morgan Stanley Healthcare conference on September 6, 2024, at 10:45 AM ET.

Why It Matters - Integra LifeSciencesโ€™ CFO presenting at a major healthcare conference signals potential strategic insights and growth prospects, influencing investor sentiment and stock performance.

News Image

Wed, 21 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - The company released its third ESG report, highlighting its values and commitment to restoring lives, which may impact its reputation and investor perception.

Why It Matters - The third ESG report highlights the company's dedication to sustainability and social responsibility, potentially attracting socially conscious investors and enhancing its market reputation.

...

IART Frequently asked questions

The highest forecasted price for IART is $40 from at Jefferies.

The lowest forecasted price for IART is $16 from Joanne Wuensch from Citigroup

The IART analyst ratings consensus are 9 buy ratings, 6 hold ratings, and 0 sell ratings.